{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:48:08Z","timestamp":1784598488713,"version":"3.55.0"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2026,3,27]]},"abstract":"\n <sec><title>BACKGROUND<\/title>Rifamycin TB preventive treatment (TPT) is critical to TB elimination. However, clinicians may be reluctant to recommend it over concerns related to drug\u2013drug interactions (DDI). In this secondary analysis of data from the 2R\n 2<\/jats:sup>\n randomised clinical trial (comparing standard dose rifampin to high-dose rifampin for TPT), we investigate if participants taking medications with potential rifampin DDI had similar TPT completion, safety, and follow-up visits compared to those without.<\/sec><sec><title>METHODS<\/title>Data\n on concomitant medications, adverse events, treatment completion, and follow-up visits were compared between participants with and without potential rifampin DDI. Analyses were conducted with R, reporting risk difference (RD) using g-computation with logistic regression.<\/sec><sec><title>RESULTS<\/title>282\n of 1,368 participants (21%) were taking essential medications with potential rifampin DDI. There was no RD in TPT completion (RD 0.04 [95% confidence interval (CI): \u22120.02; 0.09]) or adverse events (RD 0.02 [95% CI: \u22120.01; 0.06]) between participants with and without these medications.\n Individuals talking medications with potential DDI had a higher percentage of two or more unscheduled visits (12%) compared to those not taking them (5%) (\n P<\/jats:italic>\n = 0.0001).<\/sec><sec><title>CONCLUSION<\/title>In participants taking medications with potential\n rifampin DDI, rifampin TPT can be used safely without impacting completion rates. However, additional follow-up visits should be anticipated.<\/sec>\n <\/jats:p>","DOI":"10.5588\/ijtld.25.0345","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:34:41Z","timestamp":1774672481000},"page":"167-173","source":"Crossref","is-referenced-by-count":1,"title":["The impact of rifampin drug interactions on tuberculosis preventive treatment completion and safety"],"prefix":"10.5588","volume":"30","author":[{"given":"F.","family":"Fregonese","sequence":"first","affiliation":[{"name":"McGill International TB Centre, McGill University, Montreal, QC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"White","sequence":"additional","affiliation":[{"name":"Calgary Tuberculosis Services, Alberta Health Services, Calgary, AB, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.","family":"Lim","sequence":"additional","affiliation":[{"name":"Calgary Tuberculosis Services, Alberta Health Services, Calgary, AB, Canada;, Division of Respiratory Medicine, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bedingfield","sequence":"additional","affiliation":[{"name":"Calgary Tuberculosis Services, Alberta Health Services, Calgary, AB, Canada;, Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal,\n QC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.J.","family":"Cook","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada;, Provincial TB Services, British Columbia Centre for Disease Control, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gafar","sequence":"additional","affiliation":[{"name":"McGill International TB Centre, McGill University, Montreal, QC, Canada;, Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC, Canada;,\n Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gibson","sequence":"additional","affiliation":[{"name":"McGill International TB Centre, McGill University, Montreal, QC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Menzies","sequence":"additional","affiliation":[{"name":"McGill International TB Centre, McGill University, Montreal, QC, Canada;, Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC,\n Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Calgary Tuberculosis Services, Alberta Health Services, Calgary, AB, Canada;, Division of Respiratory Medicine, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2026\/00000030\/00000004\/art00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:34:46Z","timestamp":1774672486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.25.0345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,27]]}},"alternative-id":["1027-3719(20260327)30:4L.167;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.25.0345","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}